| Literature DB >> 32300916 |
Mohamad-Gabriel Alameh1, Drew Weissman2, Norbert Pardi1.
Abstract
In vitro-transcribed, messenger RNA-based infectious disease vaccines have the potential to successfully address many of the weaknesses of traditional vaccine platforms, such as the lack of potency and/or durability of vaccine protection, time-consuming, and expensive manufacturing, and, in some cases, safety issues. This optimism is fueled by a great deal of impressive recent data demonstrating that mRNA vaccines have many of the attributes that are necessary for a viable new vaccine class for human use. This review briefly describes mRNA vaccine types, discusses the most relevant and recent publications on infectious disease mRNA vaccines, and highlights the hurdles that need to be overcome to bring this promising novel vaccine modality to the clinic.Entities:
Keywords: Clinical trials; Infectious diseases; LNP; SAM; Vaccines; mRNA
Year: 2020 PMID: 32300916 DOI: 10.1007/82_2020_202
Source DB: PubMed Journal: Curr Top Microbiol Immunol ISSN: 0070-217X Impact factor: 4.291